201 results on '"D'Incà R"'
Search Results
2. T.06.7 INCIDENT COLORECTAL CANCER IN INFLAMMATORY BOWEL DISEASE
3. AF.56 COMPARATIVE ASSESSMENT OF INFLIXIMAB TROUGH LEVELS BETWEEN POINT-OF-CARE TESTING AND CURRENT STANDARD OF CARE (ENZYME LINKED IMMUNOSORBENT ASSAY) IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE
4. AF.48 COMPARATIVE ASSESSMENT OF ADALIMUMAB TROUGH LEVELS BETWEEN POINT-OF-CARE TESTING AND CURRENT STANDARD OF CARE (ENZYME LINKED IMMUNOSORBENT ASSAY) IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE
5. P329 Comparative Assessment of Adalimumab Trough Levels between Point-of-Care Testing and current Standard of Care (enzyme linked immunosorbent assay) in patients with Inflammatory Bowel Disease
6. P295 Comparative Assessment of Infliximab Trough Levels between Point-of-Care Testing and current Standard of Care (enzyme linked immunosorbent assay) in patients with Inflammatory Bowel Disease
7. T04.02.8 INFLIXIMAB ORIGINATOR, INFLIXIMAB BIOSIMILAR AND ADALIMUMAB ARE EQUALLY EFFECTIVE AND SAFE IN ULCERATIVE COLITIS AND CROHN'S DISEASE – A REAL-LIFE COHORT STUDY
8. T04.01.3 REAL LIFE COMPARISON OF DIFFERENT ANTI-TNF BIOLOGIC THERAPIES FOR ULCERATIVE COLITIS TREATMENT: A RETROSPECTIVE COHORT STUDY
9. T06.02.15 LOW PREVALENCE OF COLORECTAL NEOPLASIA IN MICROSCOPIC COLITIS: A PROSPECTIVE, MULTICENTER STUDY
10. OC.12.6 PREVALENCE OF ANAEMIA IN INFLAMMATORY BOWEL DISEASE: PRELIMINARY RESULTS OF THE OBSERVATIONAL ITALIAN MULTICENTRE IG-IBD STUDY RIDART 1
11. T04.01.21 INTESTINAL MICROBIOTA CHANGES ACCORDING TO DISEASE ACTIVITY IN PATIENTS WITH ULCERATIVE COLITIS
12. T02.02.2 INFLAMMATORY BOWEL DISEASES AND CELIAC DISEASE PATIENTS' NUTRITIONAL KNOWLEDGE
13. LOW PREVALENCE OF COLORECTAL NEOPLASIA IN MICROSCOPIC COLITIS: A PROSPECTIVE, MULTICENTER STUDY
14. Sleep disturbance in Inflammatory Bowel Disease: prevalence and risk factors – A cross-sectional study
15. P843 Intestinal microbiota changes according to disease activity in patients with ulcerative colitis
16. P415 The anti-IL-23/IL-12 agent Ustekinumab is an effective and safe induction therapy in patients with Crohn’s disease refractory or intolerant to anti-TNF: a multicentre Italian study
17. P468 Switching from adalimumab originator to ABP 501 biosimilar: a multicentre North Italian study
18. P668 Real-life comparison of different anti-TNF biologic therapies for ulcerative colitis treatment: A retrospective cohort study
19. MALDI-TOF/MS peptidomic profiling for the diagnosis of inflammatory bowel diseases
20. TERMINAL ILEUM ILEOSCOPY AND HISTOLOGY IN PATIENTS UNDERGOING HIGH-DEFINITION COLONOSCOPY WITH VIRTUAL CHROMO-ENDOSCOPY FOR CHRONIC NON-BLOODY DIARRHEA: A PROSPECTIVE MULTI-CENTER STUDY
21. OC.09.3 INFLIXIMAB DOSE-REDUCTION IN INFLAMMATORY BOWEL DISEASE (IBD) PATIENTS IN PROLONGED DEEP REMISSION: POTENTIAL IMPLICATIONS ON DE-ESCALATION STRATEGIES IN A REAL LIFE CLINICAL SETTING WITHOUT A THERAPEUTIC DRUG MONITORING (TDM) APPROACH
22. P.07.2 DISEASE ACTIVITY INFLUENCES DISABILITY AND QUALITY OF LIFE IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE – A CROSS-SECTIONAL STUDY
23. PC.01.4 PREVALENCE OF ANAEMIA IN INFLAMMATORY BOWEL DISEASE: PRELIMINARY RESULTS OF THE OBSERVATIONAL ITALIAN MULTICENTRE IG-IBD STUDY RIDART 1
24. P.07.20 EFFECTIVENESS OF VEDOLIZUMAB IN CLINICAL REMISSION PATIENTS: UNRAVELLING THE GREY ZONE IN REAL LIFE PRACTICE
25. P.07.33 MICROENCAPSULATED SODIUM BUTYRATE SIGNIFICANTLY MODIFIES THE MICROBIOTA IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE MIMICKING PREBIOTIC ACTIVITY AND PROVING EFFECTS ON THE TREATMENT OF THE DISEASE
26. OC.12.4 RAPID POINT-OF-CARE MONITORING OF ANTI-INFLIXIMAB ANTIBODIES AND CLINICAL SCORES IN INFLAMMATORY BOWEL DISEASE PATIENTS
27. P.07.32 THE QUALITY OF SLEEP IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE IS IMPAIRED INDEPENDENTLY FROM THE DISEASE ACTIVITY STATUS – A CROSS-SECTIONAL STUDY
28. P.07.8 MAGNETIZATION TRANSFER IMAGING FOR THE ASSESSMENT OF INTESTINAL FIBROSIS IN CROHN'S DISEASE
29. P.07.17 EFFICACY AND SAFETY OF VEDOLIZUMAB IN REAL LIFE: EXPERIENCE IN A TERTIARY REFERRAL CENTRE
30. OC.13.5 TERMINAL ILEUM ILEOSCOPY AND HISTOLOGY IN PATIENTS UNDERGOING HIGH-DEFINITION COLONOSCOPY WITH VIRTUAL CHROMOENDOSCOPY FOR CHRONIC NON-BLOODY DIARRHEA: A PROSPECTIVE MULTI-CENTER STUDY
31. P.07.28 PREVIOUS EXPOSURE TO INFLIXIMAB INDUCES CROSS-REACTIVITY AND AFFECTS ADALIMUMAB TROUGH LEVELS: DATA FROM A PROSPECTIVE, MULTICENTRE STUDY
32. OC.09.6 PERFORATING CROHN'S DISEASE AND EXTENSIVE COLITIS AS RISK FACTORS FOR INCIDENT CANCER: A MULTICENTER NESTED CASE-CONTROL IG-IBD STUDY AT 6 YEARS
33. P.01.34 CLEAR CELL RENAL CARCINOMA GASTRIC METASTASIS PRESENTING WITH GASTROINTESTINAL BLEEDING: A CASE REPORT
34. P650 Mechanisms of Infliximab failure: the predictive role of MMP3
35. N18 Mood disorders in a IBD population: a single-centre cohort
36. P802 Perforating Crohn's Disease and pancolitis as risk factors for incident cancer: a prospective multi-centre nested case–control IG-IBD study at 6 years
37. P655 Microencapsulated Sodium Butyrate significantly modifies the microbiota in patients with inflammatory bowel disease mimicking prebiotic activity and proving effects on the treatment of the disease
38. P199 Terminal ileum ileoscopy and histology in patients undergoing high-definition colonoscopy with virtual chromoendoscopy for chronic non-bloody diarrhoea: a prospective, multi-centre study
39. P475 Rapid point-of-care anti-drug antibodies measurement correlates with standardised T tests and facilitate a proactive therapeutic drug monitoring approach in IBD patients on anti-TNF-α maintenance therapy
40. Zinc Absorption in Normal Subjects and in Gastrointestinal Diseases
41. P.07.2 OUTCOME IN ULCERATIVE COLITIS AFTER SWITCH FROM SUBCUTANEOUS ANTI-TNF TO INTRAVENOUS ANTI-TNF: A MULTICENTRE STUDY
42. OC.11.1 PROGRAMMED CELL DEATH LIGAND-1 (PD-L1) EXPRESSION IS COUPLED WITH MICROSATELLITE INSTABILITY IN NON-FAMILIAL SMALL BOWEL CARCINOMAS ASSOCIATED OR NOT WITH COELIAC DISEASE OR CROHN'S DISEASE: RESULTS FROM THE SMALL BOWEL CANCER ITALIAN CONSORTIUM
43. P.07.3 EFFECTIVENESS OF GOLIMUMAB IN REAL LIFE – A SINGLE CENTER PROSPECTIVE STUDY
44. P.02.7 MMP3 (METALLOPROTEINASE 3): A NEW MARKER FOR ASSESSING LOSS OF RESPONSE TO INFLIXIMAB IN IBD
45. OC.16.5 IMPACT OF ADALIMUMAB'S PATIENT SUPPORT PROGRAM ON ADHERENCE TO ANTI-TNF-ALFA THERAPY IN INFLAMMATORY BOWEL DISEASE: A SINGLE CENTER ANALYSIS
46. P.07.26 QUALITY OF LIFE ASSESSMENT IN ULCERATIVE COLITIS OUTPATIENTS: A CROSS SECTIONAL STUDY
47. P.02.12 MICROBIOTA PROFILE AND DYSBIOSIS ASSESSMENT IN CLINICAL PRACTICE: A PILOT STUDY ON IBD PATIENTS
48. OC.02.5 PREVALENCE OF ANAEMIA IN INFLAMMATORY BOWEL DISEASE: PRELIMINARY RESULTS OF THE OBSERVATIONAL ITALIAN MULTICENTRE IG-IBD STUDY RIDART1
49. OC.12.3 INCIDENT CANCER IN INFLAMMATORY BOWEL DISEASE IN A PROSPECTIVE MULTICENTER NESTED CASE-CONTROL IG-IBD STUDY
50. P.02.24 EVALUATION OF QUALITY OF LIFE IN IBD PATIENTS TREATED WITH ANTI-TNFA THERAPY
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.